{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:26:58Z","timestamp":1790980018337,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ministry of Science, Technological Development and Innovation, Republic of Serbia","award":["451-03-47\/2023-01\/200161"],"award-info":[{"award-number":["451-03-47\/2023-01\/200161"]}]},{"name":"Ministry of Science, Technological Development and Innovation, Republic of Serbia","award":["451-03-47\/2023-01\/200161"],"award-info":[{"award-number":["451-03-47\/2023-01\/200161"]}]},{"name":"Ministry of Science, Technological Development and Innovation, Republic of Serbia","award":["451-03-47\/2023-01\/200161"],"award-info":[{"award-number":["451-03-47\/2023-01\/200161"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00228-024-03642-4","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T18:02:36Z","timestamp":1707760956000},"page":"697-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Understanding hemoglobin contribution to high-dose methotrexate disposition\u2014population pharmacokinetics in pediatric patients with hematological malignancies"],"prefix":"10.1007","volume":"80","author":[{"given":"Biljana","family":"\u0160kori\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Jovanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161","family":"Kuzmanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branislava","family":"Miljkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9676-5785","authenticated-orcid":false,"given":"Katarina","family":"Vu\u010di\u0107evi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"3642_CR1","unstructured":"A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia (ALL IC-BFM 2009)\u00a0(2009) Final version of therapy protocol from August-14-2009 [Internet]. https:\/\/www.bialaczka.org\/wp-content\/uploads\/2016\/10\/ALLIC_BFM_2009.pdf. Accessed June 2023"},{"issue":"8","key":"3642_CR2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/pbc.25469","volume":"62","author":"M Pillon","year":"2015","unstructured":"Pillon M, Arico M, Mussolin L, Carraro E, Conter V, Sala A, Buffardi S, Garaventa A, D\u2019Angelo P, Lo Nigro L, Santoro N, Piglione M, Lombardi A, Porta F, Cesaro S, Moleti ML, Casale F, Mura R, d\u2019Amore ES, Basso G, Rosolen A (2015) Long-term results of the AIEOP LNH-97 protocol for childhood lymphoblastic lymphoma. Pediatr Blood Cancer 62(8):1388\u20131394. https:\/\/doi.org\/10.1002\/pbc.25469","journal-title":"Pediatr Blood Cancer"},{"key":"3642_CR3","unstructured":"International protocol for the treatment of childhood anaplastic large cell lymphoma (ALCL 99)  (2000) [Internet]. https:\/\/www.skion.nl\/workspace\/uploads\/alcl-99.pdf. Accessed June 2023"},{"issue":"2","key":"3642_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13318-021-00737-6","volume":"47","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Sun L, Chen X, Zhao L, Wang X, Zhao Z, Mei S (2022) A systematic review of population pharmacokinetic models of methotrexate. Eur J Drug Metab Pharmacokinet 47(2):143\u2013164. https:\/\/doi.org\/10.1007\/s13318-021-00737-6","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"12","key":"3642_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21(12):1471\u20131482. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"issue":"8 Pt 2","key":"3642_CR6","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/clinchem\/42.8.1322","volume":"42","author":"SP Treon","year":"1996","unstructured":"Treon SP, Chabner BA (1996) Concepts in use of high-dose methotrexate therapy. Clin Chem 42(8 Pt 2):1322\u20131329","journal-title":"Clin Chem"},{"issue":"2","key":"3642_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13318-016-0338-1","volume":"42","author":"A Nader","year":"2017","unstructured":"Nader A, Zahran N, Alshammaa A, Altaweel H, Kassem N, Wilby KJ (2017) Population pharmacokinetics of intravenous methotrexate in patients with hematological malignancies: utilization of routine clinical monitoring parameters. Eur J Drug Metab Pharmacokin 42(2):221\u2013228. https:\/\/doi.org\/10.1007\/s13318-016-0338-1","journal-title":"Eur J Drug Metab Pharmacokin"},{"key":"3642_CR8","doi-asserted-by":"publisher","unstructured":"Skoric B, Kuzmanovic M, Jovanovic M, Miljkovic B, Micic D, Jovic M, Jovanovic A, Vucicevic K (2023) Methotrexate concentrations and associated variability factors in high dose therapy of children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Pediatr Hematol Oncol 40(5):446\u2013457. https:\/\/doi.org\/10.1080\/08880018.2023.2168809","DOI":"10.1080\/08880018.2023.2168809"},{"issue":"4","key":"3642_CR9","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT: PSP 2(4):e38. https:\/\/doi.org\/10.1038\/psp.2013.14","journal-title":"CPT: PSP"},{"issue":"4","key":"3642_CR10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.5937\/arhfarm71-32901","volume":"71","author":"M Roganovi\u0107","year":"2021","unstructured":"Roganovi\u0107 M, Hom\u0161ek A, Jovanovi\u0107 M, Topi\u0107 Vu\u010denovi\u0107 V, \u0106ulafi\u0107 M, Miljkovi\u0107 B, Vu\u010di\u0107evi\u0107 K (2021) Concept and utility of population pharmacokinetic and pharmacokinetic\/pharmacodynamic models in drug development and clinical practice. Arh farm 71(4):336\u2013353. https:\/\/doi.org\/10.5937\/arhfarm71-32901","journal-title":"Arh farm"},{"issue":"5","key":"3642_CR11","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.xphs.2018.01.004","volume":"107","author":"S Mei","year":"2018","unstructured":"Mei S, Li X, Jiang X, Yu K, Lin S, Zhao Z (2018) Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. J Pharm Sci 107(5):1454\u20131460. https:\/\/doi.org\/10.1016\/j.xphs.2018.01.004","journal-title":"J Pharm Sci"},{"issue":"5","key":"3642_CR12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s00280-006-0202-0","volume":"58","author":"DW Faltaos","year":"2006","unstructured":"Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, Xuan k H, Leblond V, Lechat P (2006) Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol 58(5):626\u2013633. https:\/\/doi.org\/10.1007\/s00280-006-0202-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"3642_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/bdd.2221","volume":"41","author":"ZY Shi","year":"2020","unstructured":"Shi ZY, Liu YO, Gu HY, Xu XQ, Yan C, Yang XY, Yan D (2020) Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma. Biopharm Drug Dispos 41(3):101\u2013110. https:\/\/doi.org\/10.1002\/bdd.2221","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"3642_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2710.2008.00966.x","volume":"33","author":"K Fukuhara","year":"2008","unstructured":"Fukuhara K, Ikawa K, Morikawa N, Kumagai K (2008) Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther 33(6):677\u2013684. https:\/\/doi.org\/10.1111\/j.1365-2710.2008.00966.x","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"3642_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bcp.14160","volume":"86","author":"JC Panetta","year":"2020","unstructured":"Panetta JC, Roberts JK, Huang J, Lin T, Daryani VM, Harstead KE, Patel YT, Onar-Thomas A, Campagne O, Ward DA, Broniscer A, Robinson G, Gajjar A, Stewart CF (2020) Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. Br J Clin Pharmacol 86(2):362\u2013371. https:\/\/doi.org\/10.1111\/bcp.14160","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3642_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/phar.2379","volume":"40","author":"MP Pai","year":"2020","unstructured":"Pai MP, Debacker KC, Derstine B, Sullivan J, Su GL, Wang SC (2020) Comparison of body size, morphomics, and kidney function as covariates of high-dose methotrexate clearance in obese adults with primary central nervous system lymphoma. Pharmacother 40(4):308\u2013319. https:\/\/doi.org\/10.1002\/phar.2379","journal-title":"Pharmacother"},{"issue":"3","key":"3642_CR17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/cpt.1957","volume":"108","author":"ZL Taylor","year":"2020","unstructured":"Taylor ZL, Mizuno T, Punt NC, Baskaran B, Navarro Sainz A, Shuman W, Felicelli N, Vinks AA, Heldrup J, Ramsey LB (2020) MTXPK.org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase. Clin Pharmacol Ther 108(3):635\u2013643. https:\/\/doi.org\/10.1002\/cpt.1957","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3642_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/FTD.0b013e31823615e1","volume":"33","author":"AM Johansson","year":"2011","unstructured":"Johansson AM, Hill N, Perisoglou M, Whelan J, Karlsson MO, Standing JF (2011) A population pharmacokinetic\/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Ther Drug Monit 33(6):711\u2013718. https:\/\/doi.org\/10.1097\/FTD.0b013e31823615e1","journal-title":"Ther Drug Monit"},{"issue":"6","key":"3642_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00280-019-03966-4","volume":"84","author":"S Kawakatsu","year":"2019","unstructured":"Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ, Capparelli EV (2019) Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol 84(6):1339\u20131348. https:\/\/doi.org\/10.1007\/s00280-019-03966-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3642_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pbc.22999","volume":"57","author":"P Jonsson","year":"2011","unstructured":"Jonsson P, Skarby T, Heldrup J, Schroder H, Hoglund P (2011) High dose methotrexate treatment in children with acute lymphoblastic leukaemia may be optimised by a weight-based dose calculation. Pediatric Blood Cancer 57(1):41\u201346. https:\/\/doi.org\/10.1002\/pbc.22999","journal-title":"Pediatric Blood Cancer"},{"issue":"4","key":"3642_CR21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/jcph.1349","volume":"59","author":"KH Hui","year":"2019","unstructured":"Hui KH, Chu HM, Fong PS, Cheng WTF, Lam TN (2019) Population pharmacokinetic study and individual dose adjustments of high-dose methotrexate in Chinese pediatric patients with acute lymphoblastic leukemia or osteosarcoma. J Clin Pharmacol 59(4):566\u2013577. https:\/\/doi.org\/10.1002\/jcph.1349","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3642_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-014-2614-6","volume":"75","author":"KD Wright","year":"2015","unstructured":"Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P Jr, Ward D, Gajjar A, Stewart CF (2015) Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol 75(1):27\u201335. https:\/\/doi.org\/10.1007\/s00280-014-2614-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"3642_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","volume":"67","author":"BF Kotnik","year":"2011","unstructured":"Kotnik BF, Grabnar I, Grabar PB, Dolzan V, Jazbec J (2011) Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 67(10):993\u20131006. https:\/\/doi.org\/10.1007\/s00228-011-1046-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3642_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1586\/ecp.11.57","volume":"4","author":"D Leveque","year":"2011","unstructured":"Leveque D, Santucci R, Gourieux B, Herbrecht R (2011) Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Rev Clin Pharmacol 4(6):743\u2013750. https:\/\/doi.org\/10.1586\/ecp.11.57","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"3642_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/cad.0b013e3282f21376","volume":"19","author":"C Dupuis","year":"2008","unstructured":"Dupuis C, Mercier C, Yang C, Monjanel-Mouterde S, Ciccolini J, Fanciullino R, Pourroy B, Deville JL, Duffaud F, Bagarry-Liegey D, Durand A, Iliadis A, Favre R (2008) High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs 19(3):267\u2013273. https:\/\/doi.org\/10.1097\/cad.0b013e3282f21376","journal-title":"Anticancer Drugs"},{"key":"3642_CR26","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ (Eds). NONMEM users guides (7.5.0). ICON plc, Gaithersburg, Maryland (1989\u20132021) [Internet]. https:\/\/nonmem.iconplc.com. Accessed June 2023"},{"key":"3642_CR27","unstructured":"R Core Team\u00a0(2016) R: A language and environment for statistical computing. Vienna, Austria [Internet]. http:\/\/www.R-project.org. Accessed June 2023"},{"key":"3642_CR28","unstructured":"Lexicomp Online, Lexi-Interact. Waltham, MA: UpToDate, Inc.; July 30, 2021 [Internet]. https:\/\/online.lexi.com. Accessed Oct 2022"},{"issue":"12","key":"3642_CR29","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","volume":"24","author":"AC Hooker","year":"2007","unstructured":"Hooker AC, Staatz CE, Karlsson MO (2007) Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 24(12):2187\u20132197. https:\/\/doi.org\/10.1007\/s11095-007-9361-x","journal-title":"Pharm Res"},{"issue":"1","key":"3642_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82(1):17\u201320. https:\/\/doi.org\/10.1038\/sj.clpt.6100241","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3642_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s0169-2607(98)00098-4","volume":"59","author":"J Parke","year":"1999","unstructured":"Parke J, Holford NH, Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59(1):19\u201329. https:\/\/doi.org\/10.1016\/s0169-2607(98)00098-4","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"3642_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"issue":"7","key":"3642_CR33","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40262-018-00734-0","volume":"58","author":"RJ Beechinor","year":"2019","unstructured":"Beechinor RJ, Thompson PA, Hwang MF, Vargo RC, Bomgaars LR, Gerhart JG, Dreyer ZE, Gonzalez D (2019) The population pharmacokinetics of high-dose methotrexate in infants with acute lymphoblastic leukemia highlight the need for bedside individualized dose adjustment: a report from the children\u2019s oncology group. Clin Pharmacokinet 58(7):899\u2013910. https:\/\/doi.org\/10.1007\/s40262-018-00734-0","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3642_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5937\/arhfarm72-37605","volume":"72","author":"M Jovanovi\u0107","year":"2020","unstructured":"Jovanovi\u0107 M, Vu\u010di\u0107evi\u0107 K (2020) Pediatric pharmacokinetic considerations and implications for drug dosing. Arh farm 72(3):340\u2013352. https:\/\/doi.org\/10.5937\/arhfarm72-37605","journal-title":"Arh farm"},{"issue":"9","key":"3642_CR35","doi-asserted-by":"publisher","first-page":"e46015","DOI":"10.1371\/journal.pone.0046015","volume":"7","author":"H Ruhs","year":"2012","unstructured":"Ruhs H, Becker A, Drescher A, Panetta JC, Pui CH, Relling MV, Jaehde U (2012) Population PK\/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia. PLoS ONE 7(9):e46015. https:\/\/doi.org\/10.1371\/journal.pone.0046015","journal-title":"PLoS ONE"},{"issue":"6","key":"3642_CR36","doi-asserted-by":"publisher","first-page":"822","DOI":"10.2174\/138920012800840400","volume":"13","author":"TA de Beaumais","year":"2012","unstructured":"de Beaumais TA, Jacqz-Aigrain E (2012) Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children. Curr Drug Metab 13(6):822\u2013834. https:\/\/doi.org\/10.2174\/138920012800840400","journal-title":"Curr Drug Metab"},{"issue":"8","key":"3642_CR37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/bdd.678","volume":"30","author":"Y Min","year":"2009","unstructured":"Min Y, Qiang F, Peng L, Zhu Z (2009) High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. Biopharm Drug Dispos 30(8):437\u2013447. https:\/\/doi.org\/10.1002\/bdd.678","journal-title":"Biopharm Drug Dispos"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03642-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03642-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03642-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T06:04:04Z","timestamp":1712556244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03642-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["3642"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03642-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"30 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Institute for Mother and Child Healthcare of Serbia \u201cDr Vukan \u010cupi\u0107\u201d approved the study protocol and retrospective collection of data from medical records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}